Correction: STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
In the previous version of this article it was not stated that the full data set of Vertex's 194 patient clinical study had been reported. This was incorrect as the full data set was released by the company and discussed in a conference call on April 18. That press release included a table showing changes relative to placebo, for the secondary endpoint of FEV1 showing that only the top two doses were significantly different from placebo and the highest doses had a lower efficacy than the second highest doses.
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.